Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

ABSTRACT: Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

PROVIDER: PRJNA681011 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

Project description:To clarigy the molecular mechanism underlying the IMiD-induced megakaryocytic lineage commitment in human megakaryocyte/erythrocyte progenitors, we performed transcriptome analysis of CD41-CD105+ and CD41+CD105- cells obtained from megakaryocyte/erythrocyte progenitors treated with lenalidomide for 72 hours. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. CD105-CD41+ cells showed the enrichment in the expression of genes related to megakaryocytes and platelet, whereas genes related to erythroid lineage were negatively enriched. CD41+CD105- cells expressed higher levels of transcription factors required for megakaryocyte differentiation including FLI1, RUNX1, and MEIS1. Furthermore, we performed a knockdown strategy with small interfering RNA against MEIS1 mRNA, confirming that lenalidomide-induced megakaryocyte commitment should be due to the up-regulation of MEIS1 in megakaryocyte/erythrocyte progenitors.

2021-11-25 | GSE162212 | GEO

megamiR, microRNA expression profiles during megakaryocyte-erythrocyte progenitor (MEP) differentiation

2008-06-10 | GSE10593 | GEO

megamiR, microRNA expression profiles during megakaryocyte-erythrocyte progenitor (MEP) differentiation

Project description:This collection contains microRNA expression profiling data for samples purified from umbilical cord blood, belonging to one of the followiing populations: MEP, MEGA1, MEGA2, ERY1, ERY2, ERY3. MEP: megakaryocyte-erythrocyte precursors (defined by CD34+ CD38+ IL-3Ra- CD45RA- ); MEGA1: megakaryocyte population 1 (defined by CD34+ CD61+ CD41+ CD45- ); MEGA2: megakaryocyte population 2 (defined by CD34- CD61+ CD41+ CD45- ); ERY1: erythrocyte population 1 (defined by CD34+ CD71+ GlyA- ); ERY2: erythrocyte population 2 (defined by CD34- CD71+ GlyA- ); ERY3: erythrocyte population 3 (defined by CD34- CD71+ GlyA+ ). Keywords: microRNA, miRNA, MEP, megakaryocyte, erythrocyte, lineage specification Varied numbers of samples were analyzed per population. Each sample came from one donor. Data were normalized as described (Lu et al., Nature 435, 834-838, 2005) with modifications. Average readings from water-only labeled samples were used for probe-specific background subtraction. Linear normalization among different bead sets for the same sample was performed using readings from 2 post-control probes with equal contribution. Sample normalization was subsequently carried out assuming equal total fluorescence readings.

2010-06-26 | E-GEOD-10593 | biostudies-arrayexpress

Gene expression comparisons of megakaryocyte-erythrocyte progenitors isolated from wild type and c-MybTG/c-MybTG mice

2011-01-10 | GSE19901 | GEO

Gene expression comparisons of megakaryocyte-erythrocyte progenitors isolated from wild type and c-MybTG/c-MybTG mice

Project description:Transgene insertion in proximity to the c-Myb gene disrupts c-Myb expression in megakaryocyte-erythrocyte progenitors (MEPs), resulting in skewed commitment to megakaryocyte lineage. To understand the genes regulated by c-Myb at the megakaryocyte-erythrocyte bifurcation, MEPs of c-MybTG/c-MybTG mice were examined. Detailed analysis on c-MybTG/c-MybTG is descried in the paper by Mukai et al, Mol Cell Biol 2006. The IL-7R-Lin-Sca-1–c-Kit+ fraction was subdivided into FcR loCD34+, FcRloCD34-, and FcRhiCD34+ populations. Among them, FcRloCD34- fraction was use as MEPs. MEPs from 16 wild type mice and those from 32 c-MybTG/c-MybTG mice were pooled and used for RNA purification.

2011-01-10 | E-GEOD-19901 | biostudies-arrayexpress

Consequences of GATA1 expression in Gata1- G1ME Murine Megakaryocyte/Erythrocyte Progenitor Cell Line

Project description:G1ME cells are GATA1-deficient murine bipotential megakaryocyte/erythrocyte progenitor cells derived from Gata1-negative murine ES cells. In order to assess the impact of GATA1 on gene regulation and cell differentiation, an expression construct was used to transiently produce high levels of GATA1. Cells transduced with this construct or a vector control were harvested at 18 and 42 hours, and gene expression was analyzed using Affymetrix MOE430 version 2 arrays.

2009-06-10 | GSE14980 | GEO

Development of gene expression signatures for lenalidomide treatement on megakaryocyte

Project description:Development of gene expression signatures for lenalidomide treatement on megakaryocyte

| PRJNA438898 | ENA

Consequences of GATA1 expression in Gata1- G1ME Murine Megakaryocyte/Erythrocyte Progenitor Cell Line

2009-06-10 | E-GEOD-14980 | biostudies-arrayexpress

Development of gene expression signatures for lenalidomide treatement on megakaryocyte

Project description:To clarify the machinery how lenalidomide inhibit proplatelet formation of megakaryocytes, we performed transcriptome analysis of megakaryocytes derived from human hematopoietic stem/progenitor cells in the liquid culture system with or without lenalidomide. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. Untreated megakaryocytes showed the estradiol-responded gene expression signatures, whereas the lenalidomide-treated megakaryocytes did not. Furthermore, we performed a rescue strategy with exogenous estradiol, confirming that lenalidomide-induced inhibition of proplatelet formation should be due to the deficiency of endogenous estradiol action in megakaryocytes.

2018-06-30 | GSE111994 | GEO

Megakaryocyte and erythroblast DNA in plasma and platelets

Project description:Circulating nucleic acids are present in plasma and are derived from a range of cell types, mainly cells of hematopoietic origin, enabling their use as biomarkers for diseases involving these cell types. Using cell type-specific methylation markers, we determined that megakaryocytes are major contributors to cfDNA (~26%), while erythroblasts contribute 1-4% of cfDNA in healthy individuals. Additionally, we identified megakaryocyte-derived DNA within platelets, providing non-invasive access to the megakaryocyte genome and epigenome. Analysis of cfDNA in women who have received male platelet transfusions indicates that megakaryocyte-derived cfDNA does not originate from platelets but is rather released directly from megakaryocytes. The concentration of megakaryocyte-derived cfDNA is elevated in individuals with pathologies involving increased platelet production (Essential Thrombocythemia, Idiopathic Thrombocytopenic Purpura) and decreased by bone marrow suppression (due to chemotherapy), while erythrocyte progenitor cfDNA is elevated in patients with Thalassemia. Megakaryocyte- and erythroblast-specific DNA methylation patterns may serve as novel biomarkers for pathologies involving increased or decreased thrombopoiesis and erythropoiesis.

2022-10-12 | GSE206818 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data